Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh

Co-development deal worth $265m in near-term cash will allow Akebia to tap into Otsuka's established kidney disease infrastructure, while holding the reins on key aspects of commercialization.